Stockreport

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treat [Read more]